This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, R. S.
Right arrow Articles by Talbot, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, R. S.
Right arrow Articles by Talbot, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2002, p. 3236-3242, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3236-3242.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparative Evaluation of a New Fluorescent Carboxyfluorescein Diacetate-Modified Microdilution Method for Antifungal Susceptibility Testing of Candida albicans Isolates

Robert S. Liao,1 Robert P. Rennie,1,2* and James A. Talbot1

Department of Medical Microbiology and Immunology, University of Alberta,1 National Centre for Mycology, University of Alberta Hospital, Walter C. Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada2

Received 17 January 2002/ Returned for modification 4 June 2002/ Accepted 1 July 2002

This report presents a fluorescent carboxyfluorescein diacetate (CFDA)-modified microdilution method used for the susceptibility testing of Candida albicans to amphotericin B, fluconazole, ketoconazole, itraconazole, voriconazole, and flucytosine. Four different broth microdilution susceptibility testing methods were simultaneously evaluated at 24 and 48 h. The MICs determined using the CFDA-modified method (MICcfda) were compared to those obtained by the standard broth microdilution method (MICvisual) and a procedure employing the indicator Alamar blue (MICalamar). The reference MIC was determined visually as recommended by the NCCLS M27-A protocol, and then quantified spectrophotometrically following agitation (MICspec). The CFDA-modified microdilution method was demonstrated to effectively determine the MICs for all the antifungal drugs tested at both 24 and 48 h. The results from both the MICspec and MICcfda methods yielded >80% agreement within ±1 dilution and >90% agreement within ±2 dilutions at 24 h in comparison to the reference MICvisual method, respectively. The trailing growth phenomenon that occurs with azole antifungal drugs and many strains of C. albicans did not inhibit the effectiveness of the MICspec and MICcfda methods. The MICspec and MICcfda methods shared 92.8% agreement within ±1 dilution at 24 h and 87.6% agreement within ±1 dilution at 48 h.


* Corresponding author. Present address: Department of Microbiology and Public Health, 2B3.08 Walter Mackenzie Centre, University of Alberta Hospital, 8440-112 St., Edmonton, Alberta T6G 2J2, Canada. Phone: (780) 407-7242. Fax: (780) 407-3864. E-mail: r.rennie{at}provlab.ab.ca.


Antimicrobial Agents and Chemotherapy, October 2002, p. 3236-3242, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3236-3242.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Coen, M., Bodkin, J., Power, D., Bubb, W. A., Himmelreich, U., Kuchel, P. W., Sorrell, T. C. (2006). Antifungal Effects on Metabolite Profiles of Medically Important Yeast Species Measured by Nuclear Magnetic Resonance Spectroscopy. Antimicrob. Agents Chemother. 50: 4018-4026 [Abstract] [Full Text]